Key Laboratory of Southwestern Chinese Medicine Resources, Pharmacy College, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.
Chongqing Clinical Research Center for Dermatology, Department of Dermatology, Chongqing Traditional Chinese Medicine Hospital, Chongqing 400011, China.
Molecules. 2022 Aug 25;27(17):5469. doi: 10.3390/molecules27175469.
The Src-homology 2 domain-containing phosphatase 2 (SHP2), which is encoded by PTPN11, participates in many cellular signaling pathways and is closely related to various tumorigenesis. Inhibition of the abnormal activity of SHP2 by small molecules is an important part of cancer treatment. Here, three abietane diterpenoids, named compounds -, were isolated from var. . Spectroscopic analysis was used to identify the exact structure of the compounds. The enzymatic kinetic experiment and the cellular thermal shift assay showed compound selectively inhibited SHP2 activity in vitro. Molecular docking indicated compound targeted the SHP2 catalytic domain. The predicted pharmacokinetic properties by SwissADME revealed that compound passed the majority of the parameters of common drug discovery rules. Compound restrained A549 proliferation (IC = 8.68 ± 0.96 μM), invasion and caused A549 cell apoptosis by inhibiting the SHP2-ERK/AKT signaling pathway. Finally, compound (Ajuforrestin A) is a potent and efficacious SHP2 inhibitor and may be a promising compound for human lung epithelial cancer treatment.
Src 同源结构域 2 磷酸酶 2(SHP2),由 PTPN11 编码,参与许多细胞信号通路,与多种肿瘤发生密切相关。小分子抑制 SHP2 的异常活性是癌症治疗的重要组成部分。这里,从 var. 中分离出三种松香烷二萜类化合物,命名为化合物 - 。通过光谱分析确定了化合物的准确结构。酶动力学实验和细胞热转移分析表明,化合物 在体外选择性抑制 SHP2 活性。分子对接表明化合物 靶向 SHP2 催化结构域。通过 SwissADME 预测的药代动力学特性表明,化合物 通过了大多数常见药物发现规则的参数。化合物 通过抑制 SHP2-ERK/AKT 信号通路抑制 A549 增殖(IC = 8.68 ± 0.96 μM)、侵袭并诱导 A549 细胞凋亡。最后,化合物 (Ajuforrestin A)是一种有效的 SHP2 抑制剂,可能是治疗人类肺上皮癌的有前途的化合物。